By the second week of August the calls start. A parent phones one pharmacy, then the next, then the independent two towns over, asking whether the 10 milligram is in stock before the prescription is even sent, because the chain nearest home has been empty for weeks. SingleCare, a prescription discount service, recorded a 33 percent jump in ADHD medication fills for children aged 6 to 17 in August and September over the early summer. This is the fourth back-to-school season running that opens with the same scramble.
The tidy explanation for the empty shelves is that too many people are on stimulants now: adults diagnosed late, teenagers coached by TikTok, a distracted country medicating itself. It is a story that puts the cost where cost is cheapest, on the patient who asked for the prescription. A March 2026 analysis in JAMA Health Forum says the story is wrong.
The economists Janet Currie and Anna Malinovskaya, at Yale, built a time series from 2015 to 2025 out of Symphony Health prescription data and the DEA's own production reports, covering amphetamine, lisdexamfetamine, and methylphenidate, the three drugs behind more than 90 percent of ADHD stimulant prescriptions. What they found was a supply shock, not a demand one. Across late 2022 and early 2023, several medium and smaller manufacturers cut production at nearly the same moment, and that cut lined up with a steep contraction in US imports of raw amphetamine and a more modest drop in phenylacetone, a chemical used to make it. The makers said as much themselves, citing a shortage of active ingredient behind their backorders. The market was concentrated enough to cascade: the top three held close to half of the amphetamine business, so when a few stalled, supply stalled with them.
The other favorite culprit is the DEA, which caps how much of each controlled substance can be produced in a year. Here the honest answer is more layered. The Yale authors conclude the quotas were not binding, meaning manufacturers were not pressed up against the ceiling. The DEA's own 2022 review found makers sold only about 70 percent of what they were already allowed to produce, leaving roughly a billion doses unmade. The quota was not the wall. The missing ingredient was.
That is not the same as saying the quota system works. When the DEA finally raised the amphetamine quota in October 2025, from 21.2 million grams to 26.5 million, the first real increase since the shortage began, supply eased but did not recover. A quota increase is permission, not production. It takes months to become pills, and it does nothing for an ingredient that is not arriving at the factory door.
The reason the independent two towns over had stock is not luck either. The chains run company-wide caps on how many Schedule II pills a single store may hold, and since the opioid settlements the wholesalers that supply everyone have widened their suspicious-order monitoring from opioids to stimulants. A smaller pharmacy with room under its threshold can sometimes fill what a chain, watching its own numbers, will not.
None of this reaches the patient as a decision anyone made. A CDC survey published in October 2024, fielded in late 2023, counted 15.5 million American adults with an ADHD diagnosis, a third of them taking a stimulant, and 71.5 percent of those reporting trouble filling a prescription because it wasn't available. That is not a country asking for too much. It is a supply chain that broke overseas, and agencies that spent four years arguing about quotas while a parent worked the phones in August. The fix is not to prescribe less. It is to stop treating one thin import pipeline, and three companies, as a system safe to leave alone.
